Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider in Asia that files as a foreign private issuer with the U.S. Securities and Exchange Commission. Its SEC filings, primarily on Form 6-K, provide insight into the company’s healthcare and wellness strategy, financing arrangements, governance changes and interim financial results.
Recent Form 6-K reports describe a convertible promissory note purchase agreement with an institutional investor, conversions of portions of the note into ordinary shares, and letter agreements that modify conversion timing and terms. Other filings detail a securities purchase agreement with Streeterville Capital, LLC for a warrant exercisable into newly issued ordinary shares, along with subsequent amendments that adjust the warrant exercise price and forced exercise thresholds. These documents help investors understand EUDA’s capital structure, dilution mechanisms and use of shelf registration on Form F-3.
EUDA’s 6-K filings also cover matters such as director resignations and appointments, including the addition of an independent director with ties to a key stem cell business partner, and the furnishing of unaudited condensed consolidated financial statements and operating and financial review for interim periods. Together, these filings outline both corporate governance and financial reporting aspects of the company.
On Stock Titan’s EUDA filings page, users can access these SEC submissions as they are made available through EDGAR, alongside AI-powered summaries that explain the key terms, context and potential implications of each document. This includes highlighting material terms in financing agreements, noting changes in board composition and pointing to where investors can find financial statements and narrative discussion of EUDA’s performance and prospects within its non-invasive healthcare, longevity and property management activities.
EUDA Health Holdings Limited has filed a prospectus supplement to end its continuous offering of Convertible Promissory Notes and the Ordinary Shares issuable upon their conversion under a prior prospectus. The company had the ability to issue up to US$10,000,000 of Convertible Notes and previously registered up to 5,000,000 Ordinary Shares for issuance upon conversion; as of this supplement it has sold Convertible Notes with an aggregate principal amount of $1,000,000 and issued 692,729 Ordinary Shares to the investor upon conversion. No additional Convertible Notes will be sold and no further shares will be issued under that note program. Separately, EUDA maintains a shelf registration allowing it to offer up to $100,000,000 of ordinary shares, warrants, subscription rights, debt securities and units over time. The filing also highlights the $15.0 million share-based acquisition of CK Health, for which EUDA issued 8,571,428 shares and later recognized a $14,762,562 impairment on related intangible assets, and notes that a significant shareholder holds demand registration rights for the 8,571,428 shares.
EUDA Health Holdings Limited reports that the investor in its August 2025 convertible note has agreed to convert the remaining $162,500 balance of the note into 81,250 ordinary shares. This completes conversion of the initial $1,000,000 August Note, of which $837,500 had already been converted into 569,859 shares before September 19, 2025. In addition, the investor previously received 41,620 shares at a conversion price of $0.901 per share under related letter agreements. The company also states that it does not intend to send any further put requests for additional notes under the original up to $10,000,000 purchase agreement.
EUDA Health Holdings announced a board change. Independent director Prof. Wong Kong Yew resigned effective October 23, 2025, including his roles as Chairman of the Compensation Committee and member of the Audit and Nomination Committees. The company stated his resignation was not due to any disagreement or dispute with the company or its Board.
On October 24, 2025, the Board appointed Huang Bo as an independent director, Chairman of the Compensation Committee, and member of the Audit and Nomination Committees. The Board determined Mr. Huang is independent under Nasdaq rules and Rule 10A-3. It reviewed his role at entities linked to a EUDA business partner and concluded this would not interfere with his independent judgment. The company also noted there are no related-party transactions involving Mr. Huang requiring disclosure.
EUDA Health Holdings Limited updated the terms of its August 1, 2025 $1,000,000 convertible promissory note with an institutional investor. The investor has already converted $837,500 of this note into 569,859 ordinary shares and previously received 41,620 shares at $0.901 per share under a letter agreement.
Under a new amendment signed on October 2, 2025, the investor agreed not to convert the remaining $162,500 balance until after October 31, 2025. On that date, the investor may either convert the $162,500 into 81,250 ordinary shares at $2.00 per share or request cash repayment by November 17, 2025. EUDA also reiterates that it does not intend to request the sale of additional notes under the existing purchase agreement.
EUDA Health Holdings Limited submitted a Form 6-K as a foreign private issuer to provide investors with its financial information for the six months ended June 30, 2025. The filing states that the company is furnishing unaudited condensed consolidated balance sheets as of June 30, 2025 and December 31, 2024, along with unaudited condensed consolidated statements of operations and comprehensive loss for the comparable six-month periods in 2025 and 2024.
The submission also includes an operating and financial review and prospects section discussing these interim results. This interim package gives a mid-year view of EUDA Health Holdings Limited’s financial position, performance, and management’s commentary between its annual reports on Form 20-F.
EUDA Health Holdings Ltd amended its annual report describing continued operating losses, a May 8, 2024 acquisition of CK Health Plus Sdn Bhd and significant non-cash impairment charges. The Company reported 37,153,049 ordinary shares outstanding as of December 31, 2024 and recorded a $14,755,560 impairment of intangible assets in 2024.
Management disclosed substantial doubt about the Company’s ability to continue as a going concern within one year, noting recurring losses since 2020, cash of approximately $0.2 million and a need to raise additional financing. The CK Health acquisition was settled with 8,571,428 newly issued shares valued at $15.0 million (at $1.75 per share), plus a contingent 1,000,000-share earnout tied to 2024–2025 net income milestones.
EUDA Health Holdings Limited reports a new agreement with its institutional investor around an existing convertible note. The investor originally agreed to purchase up to